nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—Proteinuria—Captopril—systemic scleroderma	0.0167	0.0167	CcSEcCtD
Methsuximide—Protein urine present—Captopril—systemic scleroderma	0.0165	0.0165	CcSEcCtD
Methsuximide—Proteinuria—Lisinopril—systemic scleroderma	0.0118	0.0118	CcSEcCtD
Methsuximide—Protein urine present—Lisinopril—systemic scleroderma	0.0117	0.0117	CcSEcCtD
Methsuximide—Hiccups—Mycophenolic acid—systemic scleroderma	0.0116	0.0116	CcSEcCtD
Methsuximide—Pancytopenia—Pentoxifylline—systemic scleroderma	0.0115	0.0115	CcSEcCtD
Methsuximide—Drowsiness—Pentoxifylline—systemic scleroderma	0.0108	0.0108	CcSEcCtD
Methsuximide—Ataxia—Captopril—systemic scleroderma	0.01	0.01	CcSEcCtD
Methsuximide—Photophobia—Lisinopril—systemic scleroderma	0.00977	0.00977	CcSEcCtD
Methsuximide—Eosinophilia—Captopril—systemic scleroderma	0.00913	0.00913	CcSEcCtD
Methsuximide—Hiccups—Mycophenolate mofetil—systemic scleroderma	0.00912	0.00912	CcSEcCtD
Methsuximide—Pancytopenia—Captopril—systemic scleroderma	0.00875	0.00875	CcSEcCtD
Methsuximide—Photophobia—Mycophenolate mofetil—systemic scleroderma	0.00856	0.00856	CcSEcCtD
Methsuximide—Weight decreased—Captopril—systemic scleroderma	0.00834	0.00834	CcSEcCtD
Methsuximide—Tension—Pentoxifylline—systemic scleroderma	0.00832	0.00832	CcSEcCtD
Methsuximide—Nervousness—Pentoxifylline—systemic scleroderma	0.00823	0.00823	CcSEcCtD
Methsuximide—Psychotic disorder—Mycophenolic acid—systemic scleroderma	0.00819	0.00819	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Captopril—systemic scleroderma	0.00815	0.00815	CcSEcCtD
Methsuximide—Vision blurred—Pentoxifylline—systemic scleroderma	0.00799	0.00799	CcSEcCtD
Methsuximide—Ataxia—Mycophenolic acid—systemic scleroderma	0.00788	0.00788	CcSEcCtD
Methsuximide—Pancytopenia—Azathioprine—systemic scleroderma	0.00764	0.00764	CcSEcCtD
Methsuximide—Leukopenia—Pentoxifylline—systemic scleroderma	0.00758	0.00758	CcSEcCtD
Methsuximide—Eosinophilia—Leflunomide—systemic scleroderma	0.00752	0.00752	CcSEcCtD
Methsuximide—Pancytopenia—Leflunomide—systemic scleroderma	0.00721	0.00721	CcSEcCtD
Methsuximide—Irritability—Lisinopril—systemic scleroderma	0.00721	0.00721	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Azathioprine—systemic scleroderma	0.00711	0.00711	CcSEcCtD
Methsuximide—Ataxia—Lisinopril—systemic scleroderma	0.0071	0.0071	CcSEcCtD
Methsuximide—Erythema multiforme—Captopril—systemic scleroderma	0.00697	0.00697	CcSEcCtD
Methsuximide—Confusional state—Pentoxifylline—systemic scleroderma	0.00697	0.00697	CcSEcCtD
Methsuximide—Pancytopenia—Mycophenolic acid—systemic scleroderma	0.00688	0.00688	CcSEcCtD
Methsuximide—Weight decreased—Leflunomide—systemic scleroderma	0.00687	0.00687	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Leflunomide—systemic scleroderma	0.00671	0.00671	CcSEcCtD
Methsuximide—Anorexia—Pentoxifylline—systemic scleroderma	0.00659	0.00659	CcSEcCtD
Methsuximide—Weight decreased—Mycophenolic acid—systemic scleroderma	0.00656	0.00656	CcSEcCtD
Methsuximide—Eosinophilia—Lisinopril—systemic scleroderma	0.00646	0.00646	CcSEcCtD
Methsuximide—Psychotic disorder—Mycophenolate mofetil—systemic scleroderma	0.00646	0.00646	CcSEcCtD
Methsuximide—Haematuria—Leflunomide—systemic scleroderma	0.00646	0.00646	CcSEcCtD
Methsuximide—Tension—Captopril—systemic scleroderma	0.0063	0.0063	CcSEcCtD
Methsuximide—Insomnia—Pentoxifylline—systemic scleroderma	0.00625	0.00625	CcSEcCtD
Methsuximide—Nervousness—Captopril—systemic scleroderma	0.00624	0.00624	CcSEcCtD
Methsuximide—Pancytopenia—Lisinopril—systemic scleroderma	0.0062	0.0062	CcSEcCtD
Methsuximide—Hiccups—Prednisone—systemic scleroderma	0.00618	0.00618	CcSEcCtD
Methsuximide—Haematuria—Mycophenolic acid—systemic scleroderma	0.00616	0.00616	CcSEcCtD
Methsuximide—Somnolence—Pentoxifylline—systemic scleroderma	0.00615	0.00615	CcSEcCtD
Methsuximide—Erythema multiforme—Azathioprine—systemic scleroderma	0.00609	0.00609	CcSEcCtD
Methsuximide—Vision blurred—Captopril—systemic scleroderma	0.00605	0.00605	CcSEcCtD
Methsuximide—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00601	0.00601	CcSEcCtD
Methsuximide—Constipation—Pentoxifylline—systemic scleroderma	0.00591	0.00591	CcSEcCtD
Methsuximide—Weight decreased—Lisinopril—systemic scleroderma	0.0059	0.0059	CcSEcCtD
Methsuximide—Proteinuria—Methotrexate—systemic scleroderma	0.00588	0.00588	CcSEcCtD
Methsuximide—Protein urine present—Methotrexate—systemic scleroderma	0.0058	0.0058	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.00577	0.00577	CcSEcCtD
Methsuximide—Erythema multiforme—Leflunomide—systemic scleroderma	0.00575	0.00575	CcSEcCtD
Methsuximide—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.0057	0.0057	CcSEcCtD
Methsuximide—Anorexia—Mometasone—systemic scleroderma	0.00569	0.00569	CcSEcCtD
Methsuximide—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00566	0.00566	CcSEcCtD
Methsuximide—Haematuria—Lisinopril—systemic scleroderma	0.00555	0.00555	CcSEcCtD
Methsuximide—Urticaria—Pentoxifylline—systemic scleroderma	0.00549	0.00549	CcSEcCtD
Methsuximide—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00547	0.00547	CcSEcCtD
Methsuximide—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00543	0.00543	CcSEcCtD
Methsuximide—Confusional state—Captopril—systemic scleroderma	0.00528	0.00528	CcSEcCtD
Methsuximide—Decreased appetite—Mometasone—systemic scleroderma	0.00519	0.00519	CcSEcCtD
Methsuximide—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.00517	0.00517	CcSEcCtD
Methsuximide—Leukopenia—Azathioprine—systemic scleroderma	0.00502	0.00502	CcSEcCtD
Methsuximide—Anorexia—Captopril—systemic scleroderma	0.005	0.005	CcSEcCtD
Methsuximide—Vision blurred—Leflunomide—systemic scleroderma	0.00499	0.00499	CcSEcCtD
Methsuximide—Tension—Mycophenolic acid—systemic scleroderma	0.00495	0.00495	CcSEcCtD
Methsuximide—Erythema multiforme—Lisinopril—systemic scleroderma	0.00494	0.00494	CcSEcCtD
Methsuximide—Nervousness—Mycophenolic acid—systemic scleroderma	0.0049	0.0049	CcSEcCtD
Methsuximide—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00488	0.00488	CcSEcCtD
Methsuximide—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.00486	0.00486	CcSEcCtD
Methsuximide—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00476	0.00476	CcSEcCtD
Methsuximide—Insomnia—Captopril—systemic scleroderma	0.00474	0.00474	CcSEcCtD
Methsuximide—Leukopenia—Leflunomide—systemic scleroderma	0.00474	0.00474	CcSEcCtD
Methsuximide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00473	0.00473	CcSEcCtD
Methsuximide—Abdominal pain—Mometasone—systemic scleroderma	0.00472	0.00472	CcSEcCtD
Methsuximide—Somnolence—Captopril—systemic scleroderma	0.00466	0.00466	CcSEcCtD
Methsuximide—Dizziness—Pentoxifylline—systemic scleroderma	0.00457	0.00457	CcSEcCtD
Methsuximide—Decreased appetite—Captopril—systemic scleroderma	0.00456	0.00456	CcSEcCtD
Methsuximide—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00452	0.00452	CcSEcCtD
Methsuximide—Constipation—Captopril—systemic scleroderma	0.00448	0.00448	CcSEcCtD
Methsuximide—Tension—Lisinopril—systemic scleroderma	0.00446	0.00446	CcSEcCtD
Methsuximide—Nervousness—Lisinopril—systemic scleroderma	0.00442	0.00442	CcSEcCtD
Methsuximide—Vomiting—Pentoxifylline—systemic scleroderma	0.0044	0.0044	CcSEcCtD
Methsuximide—Psychotic disorder—Prednisone—systemic scleroderma	0.00438	0.00438	CcSEcCtD
Methsuximide—Rash—Pentoxifylline—systemic scleroderma	0.00436	0.00436	CcSEcCtD
Methsuximide—Dermatitis—Pentoxifylline—systemic scleroderma	0.00436	0.00436	CcSEcCtD
Methsuximide—Headache—Pentoxifylline—systemic scleroderma	0.00433	0.00433	CcSEcCtD
Methsuximide—Feeling abnormal—Captopril—systemic scleroderma	0.00432	0.00432	CcSEcCtD
Methsuximide—Vision blurred—Lisinopril—systemic scleroderma	0.00429	0.00429	CcSEcCtD
Methsuximide—Gastrointestinal pain—Captopril—systemic scleroderma	0.00429	0.00429	CcSEcCtD
Methsuximide—Irritability—Prednisone—systemic scleroderma	0.00428	0.00428	CcSEcCtD
Methsuximide—Confusional state—Mycophenolic acid—systemic scleroderma	0.00415	0.00415	CcSEcCtD
Methsuximide—Abdominal pain—Captopril—systemic scleroderma	0.00414	0.00414	CcSEcCtD
Methsuximide—Anorexia—Leflunomide—systemic scleroderma	0.00412	0.00412	CcSEcCtD
Methsuximide—Nausea—Pentoxifylline—systemic scleroderma	0.00411	0.00411	CcSEcCtD
Methsuximide—Diarrhoea—Mometasone—systemic scleroderma	0.00408	0.00408	CcSEcCtD
Methsuximide—Leukopenia—Lisinopril—systemic scleroderma	0.00407	0.00407	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00395	0.00395	CcSEcCtD
Methsuximide—Anorexia—Mycophenolic acid—systemic scleroderma	0.00393	0.00393	CcSEcCtD
Methsuximide—Tension—Mycophenolate mofetil—systemic scleroderma	0.00391	0.00391	CcSEcCtD
Methsuximide—Insomnia—Leflunomide—systemic scleroderma	0.00391	0.00391	CcSEcCtD
Methsuximide—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00387	0.00387	CcSEcCtD
Methsuximide—Vomiting—Mometasone—systemic scleroderma	0.00379	0.00379	CcSEcCtD
Methsuximide—Feeling abnormal—Azathioprine—systemic scleroderma	0.00377	0.00377	CcSEcCtD
Methsuximide—Rash—Mometasone—systemic scleroderma	0.00376	0.00376	CcSEcCtD
Methsuximide—Dermatitis—Mometasone—systemic scleroderma	0.00376	0.00376	CcSEcCtD
Methsuximide—Decreased appetite—Leflunomide—systemic scleroderma	0.00375	0.00375	CcSEcCtD
Methsuximide—Confusional state—Lisinopril—systemic scleroderma	0.00374	0.00374	CcSEcCtD
Methsuximide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00374	0.00374	CcSEcCtD
Methsuximide—Headache—Mometasone—systemic scleroderma	0.00374	0.00374	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00373	0.00373	CcSEcCtD
Methsuximide—Insomnia—Mycophenolic acid—systemic scleroderma	0.00373	0.00373	CcSEcCtD
Methsuximide—Constipation—Leflunomide—systemic scleroderma	0.00369	0.00369	CcSEcCtD
Methsuximide—Somnolence—Mycophenolic acid—systemic scleroderma	0.00366	0.00366	CcSEcCtD
Methsuximide—Abdominal pain—Azathioprine—systemic scleroderma	0.00362	0.00362	CcSEcCtD
Methsuximide—Diarrhoea—Captopril—systemic scleroderma	0.00359	0.00359	CcSEcCtD
Methsuximide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00358	0.00358	CcSEcCtD
Methsuximide—Irritability—Methotrexate—systemic scleroderma	0.00358	0.00358	CcSEcCtD
Methsuximide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00357	0.00357	CcSEcCtD
Methsuximide—Feeling abnormal—Leflunomide—systemic scleroderma	0.00356	0.00356	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00356	0.00356	CcSEcCtD
Methsuximide—Nausea—Mometasone—systemic scleroderma	0.00354	0.00354	CcSEcCtD
Methsuximide—Anorexia—Lisinopril—systemic scleroderma	0.00354	0.00354	CcSEcCtD
Methsuximide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00353	0.00353	CcSEcCtD
Methsuximide—Ataxia—Methotrexate—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Methsuximide—Constipation—Mycophenolic acid—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Methsuximide—Weight decreased—Prednisone—systemic scleroderma	0.00351	0.00351	CcSEcCtD
Methsuximide—Dizziness—Captopril—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Methsuximide—Urticaria—Leflunomide—systemic scleroderma	0.00343	0.00343	CcSEcCtD
Methsuximide—Abdominal pain—Leflunomide—systemic scleroderma	0.00341	0.00341	CcSEcCtD
Methsuximide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.0034	0.0034	CcSEcCtD
Methsuximide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Methsuximide—Insomnia—Lisinopril—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Methsuximide—Vomiting—Captopril—systemic scleroderma	0.00333	0.00333	CcSEcCtD
Methsuximide—Rash—Captopril—systemic scleroderma	0.0033	0.0033	CcSEcCtD
Methsuximide—Dermatitis—Captopril—systemic scleroderma	0.0033	0.0033	CcSEcCtD
Methsuximide—Somnolence—Lisinopril—systemic scleroderma	0.0033	0.0033	CcSEcCtD
Methsuximide—Headache—Captopril—systemic scleroderma	0.00328	0.00328	CcSEcCtD
Methsuximide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00328	0.00328	CcSEcCtD
Methsuximide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00326	0.00326	CcSEcCtD
Methsuximide—Decreased appetite—Lisinopril—systemic scleroderma	0.00323	0.00323	CcSEcCtD
Methsuximide—Eosinophilia—Methotrexate—systemic scleroderma	0.00321	0.00321	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.0032	0.0032	CcSEcCtD
Methsuximide—Constipation—Lisinopril—systemic scleroderma	0.00317	0.00317	CcSEcCtD
Methsuximide—Diarrhoea—Azathioprine—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Methsuximide—Nausea—Captopril—systemic scleroderma	0.00311	0.00311	CcSEcCtD
Methsuximide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.0031	0.0031	CcSEcCtD
Methsuximide—Pancytopenia—Methotrexate—systemic scleroderma	0.00308	0.00308	CcSEcCtD
Methsuximide—Feeling abnormal—Lisinopril—systemic scleroderma	0.00306	0.00306	CcSEcCtD
Methsuximide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Methsuximide—Dizziness—Azathioprine—systemic scleroderma	0.00302	0.00302	CcSEcCtD
Methsuximide—Diarrhoea—Leflunomide—systemic scleroderma	0.00296	0.00296	CcSEcCtD
Methsuximide—Urticaria—Lisinopril—systemic scleroderma	0.00295	0.00295	CcSEcCtD
Methsuximide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00294	0.00294	CcSEcCtD
Methsuximide—Abdominal pain—Lisinopril—systemic scleroderma	0.00293	0.00293	CcSEcCtD
Methsuximide—Vomiting—Azathioprine—systemic scleroderma	0.00291	0.00291	CcSEcCtD
Methsuximide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Methsuximide—Drowsiness—Methotrexate—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Methsuximide—Rash—Azathioprine—systemic scleroderma	0.00288	0.00288	CcSEcCtD
Methsuximide—Dermatitis—Azathioprine—systemic scleroderma	0.00288	0.00288	CcSEcCtD
Methsuximide—Headache—Azathioprine—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Methsuximide—Dizziness—Leflunomide—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Methsuximide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Methsuximide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00282	0.00282	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00281	0.00281	CcSEcCtD
Methsuximide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00278	0.00278	CcSEcCtD
Methsuximide—Haematuria—Methotrexate—systemic scleroderma	0.00275	0.00275	CcSEcCtD
Methsuximide—Vomiting—Leflunomide—systemic scleroderma	0.00275	0.00275	CcSEcCtD
Methsuximide—Dizziness—Mycophenolic acid—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Methsuximide—Rash—Leflunomide—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Methsuximide—Dermatitis—Leflunomide—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Methsuximide—Nausea—Azathioprine—systemic scleroderma	0.00272	0.00272	CcSEcCtD
Methsuximide—Headache—Leflunomide—systemic scleroderma	0.00271	0.00271	CcSEcCtD
Methsuximide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00268	0.00268	CcSEcCtD
Methsuximide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Methsuximide—Vomiting—Mycophenolic acid—systemic scleroderma	0.00262	0.00262	CcSEcCtD
Methsuximide—Rash—Mycophenolic acid—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Methsuximide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Methsuximide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00258	0.00258	CcSEcCtD
Methsuximide—Headache—Mycophenolic acid—systemic scleroderma	0.00258	0.00258	CcSEcCtD
Methsuximide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00257	0.00257	CcSEcCtD
Methsuximide—Nausea—Leflunomide—systemic scleroderma	0.00257	0.00257	CcSEcCtD
Methsuximide—Vision blurred—Prednisone—systemic scleroderma	0.00255	0.00255	CcSEcCtD
Methsuximide—Diarrhoea—Lisinopril—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Methsuximide—Dizziness—Lisinopril—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Methsuximide—Erythema multiforme—Methotrexate—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Methsuximide—Nausea—Mycophenolic acid—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Methsuximide—Vomiting—Lisinopril—systemic scleroderma	0.00236	0.00236	CcSEcCtD
Methsuximide—Rash—Lisinopril—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Methsuximide—Dermatitis—Lisinopril—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Methsuximide—Headache—Lisinopril—systemic scleroderma	0.00233	0.00233	CcSEcCtD
Methsuximide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00223	0.00223	CcSEcCtD
Methsuximide—Nausea—Lisinopril—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Methsuximide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Methsuximide—Vision blurred—Methotrexate—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Methsuximide—Anorexia—Prednisone—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Methsuximide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00207	0.00207	CcSEcCtD
Methsuximide—Rash—Mycophenolate mofetil—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Methsuximide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Methsuximide—Headache—Mycophenolate mofetil—systemic scleroderma	0.00204	0.00204	CcSEcCtD
Methsuximide—Leukopenia—Methotrexate—systemic scleroderma	0.00202	0.00202	CcSEcCtD
Methsuximide—Insomnia—Prednisone—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Methsuximide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Methsuximide—Decreased appetite—Prednisone—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Methsuximide—Constipation—Prednisone—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Methsuximide—Confusional state—Methotrexate—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Methsuximide—Feeling abnormal—Prednisone—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Methsuximide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Methsuximide—Anorexia—Methotrexate—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Methsuximide—Urticaria—Prednisone—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Methsuximide—Abdominal pain—Prednisone—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Methsuximide—Insomnia—Methotrexate—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Methsuximide—Somnolence—Methotrexate—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Methsuximide—Decreased appetite—Methotrexate—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Methsuximide—Feeling abnormal—Methotrexate—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Methsuximide—Diarrhoea—Prednisone—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Methsuximide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Methsuximide—Urticaria—Methotrexate—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Methsuximide—Dizziness—Prednisone—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Methsuximide—Abdominal pain—Methotrexate—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Methsuximide—Vomiting—Prednisone—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Methsuximide—Rash—Prednisone—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Methsuximide—Dermatitis—Prednisone—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Methsuximide—Headache—Prednisone—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Methsuximide—Nausea—Prednisone—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Methsuximide—Diarrhoea—Methotrexate—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Methsuximide—Dizziness—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Methsuximide—Vomiting—Methotrexate—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Methsuximide—Rash—Methotrexate—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Methsuximide—Dermatitis—Methotrexate—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Methsuximide—Headache—Methotrexate—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Methsuximide—Nausea—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
